Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 64

Results For "24"

2128 News Found

iPHEX 2025: Global regulatory conclaves to highlight India’s role in shaping global health
News | September 03, 2025

iPHEX 2025: Global regulatory conclaves to highlight India’s role in shaping global health

This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings


Sai Life Sciences completes Phase II of production block 11 at Bidar
News | August 29, 2025

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL


Gilead’s Yeytuo approved in EU for HIV prevention
Drug Approval | August 28, 2025

Gilead’s Yeytuo approved in EU for HIV prevention

This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option


CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
News | August 26, 2025

CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA

Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission


GSK forays into oncology in India with Jemperli and Zejula
News | August 25, 2025

GSK forays into oncology in India with Jemperli and Zejula

The company is bringing precision therapies for gynaecological cancers


Briefs: Mankind Pharma, Mangalam Drugs and Organics, Veerhealth Care and Shelter Pharma
News | August 25, 2025

Briefs: Mankind Pharma, Mangalam Drugs and Organics, Veerhealth Care and Shelter Pharma

Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040


AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib
News | August 23, 2025

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study


Fortis Healthcare signs O&M agreement with Ekana Group for 550-bed hospital in Lucknow
Healthcare | August 22, 2025

Fortis Healthcare signs O&M agreement with Ekana Group for 550-bed hospital in Lucknow

The facility will be positioned as a Centre of Excellence for tertiary care services